-
Establishing a Differential Marker Profile for Pregnancy Complications Near Delivery.
Sharabi-Nov A, Kumar K, Fabjan Vodušek V, Premru Sršen T, Tul N, Fabjan T, Meiri H, Nicolaides KH, Osredkar J.
Fetal Diagn Ther 2020;47:471-484. pdf -
First trimester screening for gestational diabetes mellitus by maternal factors and markers of inflammation.
Syngelaki A, Visser GH, Krithinakis K, Wright A, Nicolaides KH.
Metabolism 2016;65:131-7. pdf -
Longitudinal changes in maternal soluble endoglin and angiopoietin-2 in women at risk of preeclampsia.
Khalil A, Maiz N, Garcia-Mandujano R, ElKhouli M, Nicolaides KH.
Ultrasound Obstet Gynecol 2014;44:402-10. pdf -
Maternal and foetal angiogenic imbalance in congenital heart defects.
Llurba E, Sánchez O, Ferrer Q, Nicolaides KH, Ruíz A, Domínguez C, Sánchez-de-Toledo J, García-García B, Soro G, Arévalo S, Goya M, Suy A, Pérez-Hoyos S, Alijotas-Reig J, Carreras E, Cabero L.
Eur Heart J 2014;35:701-7. -
Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia.
Lai J, Syngelaki A, Poon LC, Nucci M, Nicolaides KH.
Fetal Diagn Ther 2013;33:149-55. -
Maternal serum activin-A at 30-33 weeks in the prediction of preeclampsia.
Lai J, Pinas A, Syngelaki A, Poon LC, Nicolaides KH.
J Matern Fetal Neonatal Med 2013;26:733-7. -
Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11-13 weeks.
Beta J, Akolekar R, Ventura W, Syngelaki A, Nicolaides KH.
Prenat Diagn 2011;31:75-83. -
Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia.
Foidart JM, Munaut C, Chantraine F, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2010;35:680-7. -
Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia.
Akolekar R, Cruz JJ, Foidart JM, Munaut C, Nicolaides KH.
Prenat Diagn 2010;30:191-7. -
Maternal plasma inhibin A at 11-13 weeks of gestation in hypertensive disorders of pregnancy.
Akolekar R, Minekawa R, Veduta A, Romero XC, Nicolaides KH.
Prenat Diagn 2009;29:753-60. -
Maternal serum activin at 11-13 weeks of gestation in hypertensive disorders of pregnancy.
Akolekar R, Etchegaray A, Zhou Y, Maiz N, Nicolaides KH.
Fetal Diagn Ther 2009;25:320-7. -
Maternal serum inhibin-A and activin-A levels in the first trimester of pregnancies developing pre-eclampsia.
Spencer K, Cowans NJ, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;32:622-6. -
Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation.
Savvidou MD, Noori M, Anderson JM, Hingorani AD, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;32:871-6. -
Physiological distribution of placental growth factor and soluble Flt-1 in early pregnancy.
Makrydimas G, Sotiriadis A, Savvidou MD, Spencer K, Nicolaides KH.
Prenat Diagn 2008;28:175-9. -
Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction.
Savvidou MD, Yu CK, Harland LC, Hingorani AD, Nicolaides KH.
Am J Obstet Gynecol 2006;195:1668-73. -
First-trimester maternal serum activin A in pre-eclampsia and fetal growth restriction.
Ong CY, Liao AW, Munim S, Spencer K, Nicolaides KH.
J Matern Fetal Neonatal Med 2004;15:176-80. -
Maternal serum activin A and inhibin A in trisomy 18 pregnancies at 10-14 weeks.
Spencer K, Liao AW, Ong CY, Flack NJ, Nicolaides KH.
Prenat Diagn 2001;21:571-4. -
Maternal serum levels of dimeric inhibin A in pregnancies affected by trisomy 21 in the first trimester.
Spencer K, Liao AW, Ong CY, Geerts L, Nicolaides KH.
Prenat Diagn 2001;21:441-4. -
Maternal serum levels of total activin-A in first-trimester trisomy 21 pregnancies.
Spencer K, Liao AW, Skentou H, Ong CY, Nicolaides KH.
Prenat Diagn 2001;21:270-3. -
Raised maternal serum inhibin A concentration at 10 to 14 weeks of gestation is associated with pre-eclampsia.
Sebire NJ, Roberts L, Noble P, Wallace E, Nicolaides KH.
BJOG 2000;107:795-7.